332 related articles for article (PubMed ID: 34975756)
1. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.
Hayes KN; Baschant U; Hauser B; Burden AM; Winter EM
Front Endocrinol (Lausanne); 2021; 12():782118. PubMed ID: 34975756
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
4. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
5. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
6. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
Lespessailles E; Chapurlat R
Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
[TBL] [Abstract][Full Text] [Related]
7. Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.
Laurent MR; Goemaere S; Verroken C; Bergmann P; Body JJ; Bruyère O; Cavalier E; Rozenberg S; Lapauw B; Gielen E
Front Endocrinol (Lausanne); 2022; 13():908727. PubMed ID: 35757436
[TBL] [Abstract][Full Text] [Related]
8. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
Gourlay M; Franceschini N; Sheyn Y
Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
[TBL] [Abstract][Full Text] [Related]
9. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
10. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
11. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
[TBL] [Abstract][Full Text] [Related]
12. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis.
Chiodini I; Falchetti A; Merlotti D; Eller Vainicher C; Gennari L
Expert Rev Endocrinol Metab; 2020 Jul; 15(4):283-298. PubMed ID: 32584619
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-induced osteoporosis: 2019 concise clinical review.
Adami G; Saag KG
Osteoporos Int; 2019 Jun; 30(6):1145-1156. PubMed ID: 30805679
[TBL] [Abstract][Full Text] [Related]
15. The 2023 Guidelines for the management and treatment of glucocorticoid-induced osteoporosis.
Tanaka Y; Soen S; Hirata S; Okada Y; Fujiwara S; Tanaka I; Kitajima Y; Kubota T; Ebina K; Takashi Y; Inoue R; Yamauchi M; Okubo N; Ueno M; Ohata Y; Ito N; Ozono K; Nakayama H; Terauchi M; Tanaka S; Fukumoto S
J Bone Miner Metab; 2024 Mar; 42(2):143-154. PubMed ID: 38538869
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
Lems WF; Saag K
Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
[TBL] [Abstract][Full Text] [Related]
18. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced osteoporosis: an overview with focus on its prevention and management.
Anastasilaki E; Paccou J; Gkastaris K; Anastasilakis AD
Hormones (Athens); 2023 Dec; 22(4):611-622. PubMed ID: 37755658
[TBL] [Abstract][Full Text] [Related]
20. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Byun Robinson A; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1095-1110. PubMed ID: 28585410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
